I kliniske undersøgelser oplevede cirka 20% af infliximabbehandlede patienter sammenlignet med cirka 10% af placebobehandlede patienter en infusionsrelateret reaktion.
In clinical studies, approximately 20% of infliximab-treated patients compared with approximately 10% of placebo- treated patients experienced an infusion-related effect.